IFRX
InflaRx N.V.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$389.59M
P/E Ratio
—
EPS
$-0.73
Beta
2.44
52W High
$2.95
52W Low
$0.71
50-Day MA
$1.54
200-Day MA
$1.24
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About InflaRx N.V.
InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company is headquartered in Jena, Germany.
Fundamentals
| Revenue (TTM) | 29,330 |
| Gross Profit (TTM) | $-7.23M |
| EBITDA | $-42.43M |
| Operating Margin | -144770.00% |
| Return on Equity | -79.90% |
| Return on Assets | -39.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.59 |
| Price-to-Book | 8.50 |
| Price-to-Sales (TTM) | 13282.52 |
| EV/Revenue | 9341.62 |
| EV/EBITDA | 0.50 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -80.80% |
| Shares Outstanding | $147.29M |
| Float | $60.02M |
| % Insiders | 2.94% |
| % Institutions | 12.89% |
Historical Volatility
HV 10-Day
64.34%
HV 20-Day
118.28%
HV 30-Day
130.30%
HV 60-Day
104.23%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($7.34 target)
1
Strong Buy5
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 5/23/2026